These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 29289262

  • 1. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F, Li S, Wang T, Shi J, Wang G.
    Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
    [Abstract] [Full Text] [Related]

  • 2. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T.
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [Abstract] [Full Text] [Related]

  • 3. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T, Hozumi H, Yasui H, Suzuki Y, Karayama M, Furuhashi K, Enomoto N, Nakamura Y, Inui N, Suda T.
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [Abstract] [Full Text] [Related]

  • 4. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, Aihara K, Ikezoe K, Sokai A, Nakatsuka Y, Taguchi Y, Hatta K, Noma S, Kobashi Y, Yoshizawa A, Oga T, Hirai T, Chin K, Nagai S, Izumi T, Mimori T, Mishima M.
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [Abstract] [Full Text] [Related]

  • 5. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N, Okamoto M, Kaieda S, Fujimoto K, Ebata T, Tajiri M, Nakamura M, Tominaga M, Wakasugi D, Kawayama T, Kuwana M, Mimori T, Ida H, Hoshino T.
    Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
    [Abstract] [Full Text] [Related]

  • 6. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z, Cao M, Plana MN, Liang J, Cai H, Kuwana M, Sun L.
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [Abstract] [Full Text] [Related]

  • 7. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, Yamanaka H.
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [Abstract] [Full Text] [Related]

  • 8. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study.
    Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, Sumikawa H, Johkoh T, Nakashima R, Imura Y, Mimori T, Suda T.
    PLoS One; 2015 Dec; 10(3):e0120313. PubMed ID: 25789468
    [Abstract] [Full Text] [Related]

  • 9. Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies.
    Sato S, Murakami A, Kuwajima A, Takehara K, Mimori T, Kawakami A, Mishima M, Suda T, Seishima M, Fujimoto M, Kuwana M.
    PLoS One; 2016 Dec; 11(4):e0154285. PubMed ID: 27115353
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.
    Temmoku J, Sato S, Fujita Y, Asano T, Suzuki E, Kanno T, Furuya MY, Matsuoka N, Kobayashi H, Watanabe H, Koga T, Shimizu T, Kawakami A, Migita K.
    Medicine (Baltimore); 2019 May; 98(20):e15578. PubMed ID: 31096460
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of usefulness in surfactant protein D as a predictor of mortality in myositis-associated interstitial lung disease.
    Kaieda S, Gono T, Masui K, Nishina N, Sato S, Kuwana M, A Multicenter Retrospective Cohort of Japanese Patients with Myositis-associated ILD (JAMI) investigators.
    PLoS One; 2020 May; 15(6):e0234523. PubMed ID: 32525903
    [Abstract] [Full Text] [Related]

  • 12. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody.
    Isoda K, Kotani T, Takeuchi T, Kiboshi T, Hata K, Ishida T, Otani K, Kamimori T, Fujiwara H, Shoda T, Makino S.
    Rheumatol Int; 2017 Aug; 37(8):1335-1340. PubMed ID: 28451794
    [Abstract] [Full Text] [Related]

  • 13. [The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases].
    Xie MM, Yan X, Li H, Ding JJ, Gui XH, Liu Y, Wang YS, Chen ZY, Cai HR.
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Aug 12; 41(8):616-621. PubMed ID: 30138971
    [Abstract] [Full Text] [Related]

  • 14. Predictive value of serum markers for the development of interstitial lung disease in patients with polymyositis and dermatomyositis: a comparative and prospective study.
    Chen F, Lu X, Shu X, Peng Q, Tian X, Wang G.
    Intern Med J; 2015 Jun 12; 45(6):641-7. PubMed ID: 25827843
    [Abstract] [Full Text] [Related]

  • 15. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
    Li L, Wang H, Wang Q, Wu C, Liu C, Zhang Y, Cheng L, Zeng X, Zhang F, Li Y.
    J Neurol Sci; 2019 Feb 15; 397():123-128. PubMed ID: 30616054
    [Abstract] [Full Text] [Related]

  • 16. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM, Zou RY, Li Y, Liu Y, Chen LL, Liu XQ, Zhao Q, Ding JJ, Chen ZY, Cai HR.
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct 12; 42(10):765-770. PubMed ID: 31594111
    [Abstract] [Full Text] [Related]

  • 17. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.
    Yura H, Sakamoto N, Satoh M, Ishimoto H, Hanaka T, Ito C, Hasegawa T, Tanaka S, Miyamura T, Nakashima S, Hara A, Kakugawa T, Oda K, Kido T, Obase Y, Ishimatsu Y, Yatera K, Kawakami A, Mukae H.
    Respir Med; 2017 Nov 12; 132():189-194. PubMed ID: 29229096
    [Abstract] [Full Text] [Related]

  • 18. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S, Okamoto M, Kaieda S, Fujimoto K, Nagata S, Tominaga M, Nakamura M, Zaizen Y, Nouno T, Koga T, Kawayama T, Kuwana M, Ida H, Hoshino T.
    Respir Investig; 2018 Nov 12; 56(6):464-472. PubMed ID: 30150008
    [Abstract] [Full Text] [Related]

  • 19. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
    Asakawa K, Yoshizawa K, Aoki A, Kimura Y, Tanaka T, Ohashi K, Hayashi M, Kikuchi T, Sato S, Takada T.
    Clin Rheumatol; 2020 Jul 12; 39(7):2171-2178. PubMed ID: 32056068
    [Abstract] [Full Text] [Related]

  • 20. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies.
    Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, Muro Y, Sakairi T, Hisada T, Kurabayashi M.
    Respir Med; 2018 Jul 12; 140():1-5. PubMed ID: 29957268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.